Novo-Nordisk A/S
NVO Real Time Price USD$NVO is featured in our Tom Carper strategy.
All StrategiesRecent trades of NVO by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in NVO holdings by institutional investors
Quarterly net insider trading by NVO's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$120,000 Jan 15, 2026 Issue: None
-
$70,000 Jan 14, 2026 Issue: Pharmacy Health Issues Medicare/Medicaid Consumer Issues/Safety/Products
-
$60,000 Jan 09, 2026 Issue: Budget/Appropriations Health Issues
-
$1,730,000 Oct 20, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$1,050,000 Jul 16, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$2,330,000 Apr 18, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark
-
$1,240,000 Jan 17, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark
-
$780,000 Oct 18, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$1,060,000 Jul 19, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$1,490,000 Apr 18, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$60,000 Feb 07, 2024 Issue: Budget/Appropriations Pharmacy Medicare/Medicaid Health Issues
-
$600,000 Oct 19, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
NVO Estimated quarterly lobbying spending
NVO Revenue by Segment or Geography
New NVO patent grants
-
Patent Title: Dose setting mechanism for an injection device and having a preset feature Jun. 06, 2017
-
Patent Title: Antibodies that bind peptidoglycan recognition protein 1 May. 30, 2017
-
Patent Title: Truncated glp-1 derivatives and their therapeutical use May. 23, 2017
-
Patent Title: N-terminal modified fgf21 compounds May. 23, 2017
-
Patent Title: Injection device with integrated needle shield May. 16, 2017
-
Patent Title: Rotary sensor module with resynchronization feature May. 16, 2017
-
Patent Title: Revolving needle magazine May. 09, 2017
-
Patent Title: Drug delivery device with shield operated needle actuator May. 02, 2017
-
Patent Title: System for optimizing a drug dosage regimen over time May. 02, 2017
-
Patent Title: Drug delivery injection pen with add-on dose capturing and display module Apr. 18, 2017
-
Patent Title: System for optimizing a patient's drug dosage regimen over time Apr. 11, 2017
-
Patent Title: Automatic injection device with a top release mechanism Apr. 11, 2017
-
Patent Title: Frost protected injection device Apr. 11, 2017
-
Patent Title: Modified enterokinase light chain Apr. 04, 2017
-
Patent Title: Medical injection system comprising a medical injection device and a dose limiter module Mar. 28, 2017
-
Patent Title: Drug delivery device and logging module assembly Mar. 28, 2017
-
Patent Title: Treating diabetes melitus using insulin injections with less than daily injection frequency Mar. 28, 2017
-
Patent Title: Amylin and calcitonin receptor agonist Mar. 14, 2017
-
Patent Title: Medical skin mountable device Mar. 14, 2017
-
Patent Title: Shield lock for spring driven injection device Mar. 07, 2017
-
Patent Title: Antibodies against tissue factor pathway inhibitor Feb. 21, 2017
-
Patent Title: Method for producing acylated peptides Feb. 07, 2017
-
Patent Title: Double-acylated glp-1 derivatives Jan. 31, 2017
-
Patent Title: Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) Jan. 24, 2017
-
Patent Title: Torsion-spring based wind-up auto injector pen with dial-up/dial-down mechanism Jan. 03, 2017
-
Patent Title: Double-acylated glp-1 derivatives Dec. 27, 2016
-
Patent Title: Injection device comprising an optical sensor Dec. 20, 2016
-
Patent Title: Selective elimination of erosive cells Dec. 06, 2016
-
Patent Title: Insulin derivatives containing additional disulfide bonds Dec. 06, 2016
-
Patent Title: Method and system for self-management of a disease Nov. 22, 2016
-
Patent Title: Derivatives of glp-1 like peptides, and uses thereof Nov. 22, 2016
-
Patent Title: Factor viii fusion protein Nov. 15, 2016
-
Patent Title: Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (cmp-sa-peg) as modified nucleotide sugars via anion exchange chromatography Nov. 15, 2016
-
Patent Title: Automatic injection device with reset feature Nov. 08, 2016
-
Patent Title: Glucagon analogues Nov. 08, 2016
-
Patent Title: Glucagon analogues Nov. 08, 2016
-
Patent Title: Regulation of food preference using glp-1 agonists Nov. 08, 2016
-
Patent Title: Reminder programming device and method Nov. 01, 2016
-
Patent Title: Insulin formulations Nov. 01, 2016
-
Patent Title: Fgf21 derivatives with albumin binder a-b-c-d-e- and their use Nov. 01, 2016
-
Patent Title: Stable, protracted glp-1/glucagon receptor co-agonists for medical use Oct. 25, 2016
-
Patent Title: Injection device with an end of dose feedback mechanism Oct. 04, 2016
-
Patent Title: Method and apparatus for assisting patients in self-administration of medication Oct. 04, 2016
-
Patent Title: Injection pen with mechanical dose display comprising large ciphers Sep. 27, 2016
-
Patent Title: Glp-1 prodrugs Sep. 27, 2016
-
Patent Title: Purification of insulin Sep. 20, 2016
-
Patent Title: Counter current purification of polypeptides Sep. 13, 2016
-
Patent Title: Humanized anti-human nkg2a monoclonal antibody Aug. 23, 2016
-
Patent Title: Preparative rp-hplc method for purifying peptides Aug. 23, 2016
-
Patent Title: Combination therapy to enhance nk cell mediated cytotoxicity Aug. 16, 2016
Federal grants, loans, and purchases
Estimated quarterly amount awarded to NVO from public contracts
Recent insights relating to NVO
Recent picks made for NVO stock on CNBC
ETFs with the largest estimated holdings in NVO
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $NVO stock a Buy, Sell, or Hold?
- What is the price target for $NVO stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $NVO stock?
- Who owns the most shares of $NVO stock?
- What funds own $NVO stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NVO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.